Acta Clinica Belgica最新文献

{"title":"Evaluation of the predictive performance of CD64 and CD69 markers in the early diagnosis of bloodstream infections.","authors":"Göksel Bilir, Mümtaz Cem Şirin, Emel Sesli Çetin, Buket Arıdoğan","doi":"10.1080/17843286.2026.2748010","DOIUrl":"https://doi.org/10.1080/17843286.2026.2748010","url":null,"abstract":"<p><strong>Background: </strong>Bloodstream infection (BSI) is a leading cause of global morbidity and mortality. This study aimed to evaluate the predictive performance of CD64 and CD69, together with other cell surface markers, for early diagnosis of BSI and to compare them with conventional inflammatory markers.</p><p><strong>Methods: </strong>Expression levels of neutrophil and monocyte CD11b, CD14, CD64, and CD69 were measured by flow cytometry. Procalcitonin, C-reactive protein-to-albumin ratio, sTREM-1, calprotectin, and hematological ratios were also analyzed. Diagnostic performance was assessed using ROC analysis, and logistic regression, including Firth penalization, was performed to identify independent predictors of BSI.</p><p><strong>Results: </strong>Procalcitonin, C-reactive protein-to-albumin ratio, sTREM-1, calprotectin, neutrophil-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, monocyte-to-HDL ratio, nCD11b, mCD11b, nCD14, mCD14, nCD64, mCD64, nCD69, and mCD69 differed significantly between the culture-confirmed BSI group (<i>n</i> = 130) and the culture-negative control group (<i>n</i> = 50) (<i>p</i> < 0.05). Among cell surface markers, mCD69 demonstrated the highest diagnostic accuracy (AUC = 0.948), followed by nCD14 (AUC = 0.897) and nCD64 (AUC = 0.884). The gram-negative bacteremia group exhibited the highest median values of procalcitonin, C-reactive protein-to-albumin ratio, sTREM-1, calprotectin, neutrophil-to-lymphocyte ratio, and nCD14, and the lowest median lymphocyte-to-monocyte ratio compared with the gram‑positive bacteremia and fungemia groups. Significant positive correlations were observed between cell surface markers and conventional inflammatory markers (<i>p</i> < 0.05). In logistic regression analysis, mCD69 and procalcitonin were statistically associated with BSI (<i>p</i> < 0.05).</p><p><strong>Conclusion: </strong>Cell surface markers, particularly mCD69, demonstrated good discriminatory performance between BSI and control groups. Their combined use with conventional markers may provide useful complementary information; however, future validation studies including alternative comparator groups are required before routine clinical implementation.</p>","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":" ","pages":"1-14"},"PeriodicalIF":1.4,"publicationDate":"2026-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149217251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pitfalls in the diagnosis of diffuse large B-cell lymphoma with flow cytometry.","authors":"Victor Pas, Mattias Hofmans, Stijn Lambrecht","doi":"10.1080/17843286.2026.2742317","DOIUrl":"https://doi.org/10.1080/17843286.2026.2742317","url":null,"abstract":"<p><strong>Introduction: </strong>Although flow cytometry (FCM) is not required for the diagnosis of diffuse large B-cell lymphoma (DLBCL) according to World Health Organization criteria, FCM plays an auxiliary role in the work-up of non-Hodgkin lymphomas. The sensitivity of FCM for DLBCL remains variable. Literature reports a detection rate of 63% to 97%. This study aims to identify factors that may influence the sensitivity.</p><p><strong>Methods: </strong>A retrospective data-analysis was performed on 53 patient samples with a diagnosis of DLBCL. A lymphoma screening panel was performed on the same sample as the histopathological diagnosis. Sample quality was compared between cases with and without FCM-detected disease. The immunophenotype of DLBCL in FCM-detected cases was assessed and compared with normal B-cells.</p><p><strong>Results: </strong>Detection rate was found at 67.9%. Average viability was 57% when disease was detected on FCM, and 28% when it was not. Detection rate in lymphoid samples was 85%, and in non-lymphoid tissue 57%. The immunophenotype of DLBCL was: CD45+ (100%), CD19+ (97%), CD20+ (100%), CD5- (89%), and CD10- (58%). Side scatter was high in most cases, and light chain restriction was not detected in 19%.</p><p><strong>Discussion: </strong>This study identifies multiple factors that influence the sensitivity to detect DLBCL cells by flow cytometry in biopsy samples. Non-lymphoid samples of low viability should be considered as limited in diagnostic utility. From an analytical perspective, the gating strategy should be optimized to lower the risk of missing lymphoma cells with a high SSC and the absence of light chain restriction should not exclude the diagnosis of DLBCL in FCM.</p>","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":" ","pages":"1-8"},"PeriodicalIF":1.4,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149128862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CAR T-cell therapy for relapsed and refractory B-cell non-Hodgkin lymphoma: a single-centre 5-year real-world experience study at Ghent University Hospital.","authors":"Julie Vandewiele, Chiel Gharakhani, Ciel De Vriendt, Willem Daneels","doi":"10.1080/17843286.2026.2736302","DOIUrl":"https://doi.org/10.1080/17843286.2026.2736302","url":null,"abstract":"<p><strong>Background: </strong>Relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) remains challenging to treat, particularly in patients ineligible for high-dose chemotherapy and autologous stem cell transplantation. Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising treatment.</p><p><strong>Aims: </strong>We describe the epidemiology, demographics and outcomes of patients receiving CAR T-cell therapy for R/R DLBCL (including transformed follicular lymphoma [TFL]), high-grade B-cell lymphoma (HGBCL) and mantle cell lymphoma (MCL) at Ghent University Hospital between 2019 and 2024. We assessed associations between disease subtype, remission status, acute toxicity and survival.</p><p><strong>Methods: </strong>We retrospectively analyzed 84 eligible patients, of whom 83 received CAR T-cell infusion with tisagenlecleucel (<i>n</i>=20), axicabtagene ciloleucel (<i>n</i>=53) or brexucabtagene autoleucel (<i>n</i>=10). The cohort included DLBCL (<i>n</i>=47), TFL (<i>n</i>=13), HGBCL (<i>n</i>=13) and MCL (<i>n</i>=10). The objective response rate (ORR) at 1 month was 85.6%, with a complete response (CR) rate of 49.4%. At a median follow-up of 11.7 months, ORR increased to 90.3% and CR to 68.7%. Median overall survival was 29.9 months. Patients achieving PR/CR at 1 month had significantly improved long-term survival (p=0.002). Lower total metabolic tumor volume at infusion was associated with a trend toward better survival. Cytokine release syndrome (CRS) occurred in 90.4%, predominantly low grade, with grade 3-4 CRS in 1.2%. Immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in 65.1%, with grade 3-4 events in 15.6%.</p><p><strong>Conclusion: </strong>This real-world cohort confirms high response rates and favorable survival following CAR T-cell therapy in R/R B-NHL and explores potential predictive markers associated with long-term survival.</p>","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":" ","pages":"1-13"},"PeriodicalIF":1.4,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149128929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Testing the national guidelines for pyelonephritis against the local setting in a Belgian secondary care emergency department.","authors":"Simon Fagart, Reza Soleimani, Sebastien Van de Velde, Charles Descamps","doi":"10.1080/17843286.2026.2653687","DOIUrl":"10.1080/17843286.2026.2653687","url":null,"abstract":"","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":" ","pages":"480-482"},"PeriodicalIF":1.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147595524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Belgian recommendations for tissue diagnosis of amyloidosis.","authors":"Amélie Dendooven, Annelore Vandendriessche, Priyanka Joseph Koshy, Frank Timmermans, Marijn Speeckaert, Nicolas Kint, Lucas Van Aelst, Marie-Christiane Vekemans, Nathalie Meuleman, Anne-Catherine Pouleur, Antoine Bondue, Steven Droogmans, Philippe Debonnaire, Jan De Bleecker, Amaryllis Van Craenenbroeck, Rodrigo Gallardo, Joost Schymkowitz, Frédéric Rousseau, Francis Impens, Simon Devos, Michel Delforge","doi":"10.1080/17843286.2026.2660739","DOIUrl":"10.1080/17843286.2026.2660739","url":null,"abstract":"<p><strong>Background: </strong>Amyloidosis is a disorder caused by the extracellular deposition of misfolded protein fibrils, leading to organ dysfunction. Diagnosis remains challenging due to non-specific clinical presentations and the diversity of amyloid subtypes. Accurate identification of the amyloid precursor protein is key for prognostication and treatment strategy.</p><p><strong>Objectives: </strong>This document aims to provide practical recommendations for the tissue diagnosis of amyloidosis within the Belgian healthcare context. It targets clinicians managing amyloidosis patients and pathologists evaluating biopsies with suspected amyloid deposits.</p><p><strong>Methods: </strong>A structured PubMed search ('amyloidosis AND biopsy AND stain*'; 'amyloidosis AND mass spectro*') was conducted in August 2025. After exclusion of case reports, preclinical studies, and Alzheimer-related articles, 298 publications were reviewed. Recommendations were formulated based on available evidence and discussed among Belgian clinical and pathology experts.</p><p><strong>Results: </strong>Key recommendations emphasize that tissue biopsies remain essential for amyloidosis diagnosis and typing. Congo red staining with birefringence and fluorescence confirmation is required. Immunohistochemistry and immunofluorescence are first-line subtyping tools, while mass spectrometry serves as a reference method when results remain inconclusive. Centralization of complex analyses in experienced centres is encouraged.</p><p><strong>Conclusions: </strong>These recommendations promote standardized, early and accurate tissue diagnosis of amyloidosis in Belgium, supporting optimal patient management and harmonization of diagnostic practices across institutions.</p>","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":" ","pages":"427-440"},"PeriodicalIF":1.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147786555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tuberculosis versus immune-related bronchiolitis under immune checkpoint inhibitor - a diagnostic challenge.","authors":"Clara Moreno, Nieves Martinez Chanza, Lou Gonzalez Garcia, Ana Veron Sanchez, Maxime Ilzkovitz, Aspasia Georgala","doi":"10.1080/17843286.2026.2665158","DOIUrl":"10.1080/17843286.2026.2665158","url":null,"abstract":"<p><strong>Introduction: </strong>Immune checkpoint inhibitors (ICIs) improve survival in multiple malignancies but may induce immune-related adverse events (irAEs), including immune-related bronchiolitis (IRB). Radiologic patterns frequently overlap with infectious diseases, particularly tuberculosis (TB), whose reactivation risk may be increased by ICIs via disruption of granuloma integrity. Differentiation between IRB and TB is challenging, especially in patients from endemic areas.</p><p><strong>Case presentation: </strong>We report the case of a 53-year-old Turkish man with metastatic clear-cell renal cell carcinoma, who underwent right nephrectomy followed by nivolumab plus ipilimumab. Four months after treatment, he developed fatigue, dyspnea, productive cough, and weight loss. Chest CT scan showed centrilobular nodules with a tree-in-bud pattern. QuantiFERON® testing was positive. Bronchoalveolar lavage showed lymphocyte predominance with no infectious or neoplastic cells. Transbronchial biopsy demonstrated non-caseating granulomas. PCR for Mycobacterium tuberculosis was negative, and cultures were pending. Given the overlap between IRB and TB, empirical quadruple anti-TB therapy and inhaled corticosteroids were initiated and immunotherapy was temporarily discontinued. After 2 months, given negative mycobacterial cultures and significant hepatotoxicity, isoniazid was discontinued, rifampicin was carefully reintroduced under close monitoring, and the total anti-TB treatment duration was shortened to 4 months. The patient subsequently showed gradual improvement in respiratory symptoms, biomarkers, and radiologic findings.</p><p><strong>Conclusion: </strong>This case illustrates the challenge of distinguishing IRB from TB in ICI-treated patients. Empirical anti-TB therapy may be warranted in high-risk settings despite absent microbiological confirmation but carries toxicity and complicates oncologic management. Pre-treatment latent TB screening and multidisciplinary decision-making are essential to balance infection control with cancer therapy.</p>","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":" ","pages":"467-472"},"PeriodicalIF":1.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147786641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world evidence on In-hospital statin use and mortality in geriatric patients.","authors":"Lise Monsieur, Inez Schets, Roland Rössler, Yesuneh Tefera Mekasha, Nele Van Den Noortgate, Bart De Spiegeleer, Sileshi Belew, Evelien Wynendaele, Anton De Spiegeleer","doi":"10.1080/17843286.2026.2684717","DOIUrl":"10.1080/17843286.2026.2684717","url":null,"abstract":"<p><strong>Background: </strong>The role of statins in individuals older than 75 years, particularly those with frailty, remains unclear. Recent studies suggest survival benefits of chronic statin use, independent of cardiovascular status. However, survival effects of statins during acute hospitalisation in geriatric patients are unknown.</p><p><strong>Objective: </strong>To examine the association between in-hospital statin exposure and all-cause in-hospital mortality among patients admitted to an acute geriatric ward.</p><p><strong>Methods: </strong>A retrospective observational cohort study of patients ≥ 75 years admitted to a geriatric ward was conducted between 9 December 2022 and 24 July 2023. Exposure was defined as statin administration on day 2 after admission. Patients were followed until death or discharge. The outcome was in-hospital all-cause mortality. Multivariable logistic regression models were adjusted for age, sex, comorbidity burden, and functional status measured by handgrip strength. Sensitivity analyses included additional adjustment for, or stratification by, prior atherosclerotic cardiovascular disease (ASCVD) and systemic inflammation assessed by C-reactive protein (CRP).</p><p><strong>Results: </strong>Among 545 patients, in-hospital statin use was associated with a 6.3% absolute risk reduction or 49% adjusted odds reduction (OR 0.5, 95% CI [0.3-1.0]) for in-hospital mortality compared with non-use. Additional adjustment for ASCVD (OR 0.5, 95% CI [0.3-1.1]) or CRP (OR 0.6, 95% CI [0.3-1.2]) yielded similar results. Mortality reductions were comparable in secondary and primary prevention subgroups (OR 0.5 and 0.6, respectively). No significant interactions were observed.</p><p><strong>Conclusions: </strong>In-hospital statin exposure was associated with lower in-hospital mortality among acutely hospitalised older adults. Prospective randomized studies are warranted to assess causality and inform clinical practice.</p>","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":" ","pages":"375-384"},"PeriodicalIF":1.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148206309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What Europe should (not) learn from the new Dietary Guidelines for Americans.","authors":"Lukas Standaert, Nerea Fordel, Wim Van Biesen, Marijn Speeckaert, Charlotte Delrue","doi":"10.1080/17843286.2026.2684730","DOIUrl":"10.1080/17843286.2026.2684730","url":null,"abstract":"","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":" ","pages":"473-479"},"PeriodicalIF":1.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148206425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implementation of tumour treating fields for glioblastoma in Belgium: real-world outcomes from a Belgian tertiary centre.","authors":"Annelies Feyaerts, Maarten Lambrecht, Steven De Vleeschouwer, Julie Lambert, Lukas Marcelis, Karolien Goffin, Joost Dejaegher, Sarah Cappelle, Philippe Demaerel, Paul M Clement","doi":"10.1080/17843286.2026.2701965","DOIUrl":"10.1080/17843286.2026.2701965","url":null,"abstract":"<p><strong>Objectives: </strong>Tumour treating fields (TTF) improve survival in newly diagnosed glioblastoma (GBM) in randomized trials, but real-world impact in Belgium remains unclear due to limited access and lack of reimbursement. This study evaluates progression-free survival (PFS) and overall survival (OS) in Belgian patients with newly diagnosed GBM treated with TTF alongside standard therapy.</p><p><strong>Methods: </strong>We conducted a retrospective single-centre cohort study at UZ Leuven including patients with histologically confirmed newly diagnosed GBM treated with TTF between April 2019 and July 2026. TTF was initiated during adjuvant temozolomide. Clinical, molecular and treatment data were extracted from institutional records. Primary outcomes were PFS and OS from diagnosis. Kaplan-Meier survival analyses were performed, including subgroup analyses by MGMT status, device adherence (>75%), and extent of resection.</p><p><strong>Results: </strong>Twenty-eight patients were analysed (median age 52 years; 71% male). MGMT promoter methylation was present in 29% and gross total resection was achieved in 50%. Adherence exceeded 75% in 96%. Median PFS was 6.8 months and median OS 24.6 months, comparing favourably with EF-14 outcomes. ECOG status predicted survival (<i>p</i> = 0.04). Survival was not associated with MGMT status or adherence. Gross total resection showed a clinically meaningful association with improved OS (30.7 vs 8.2 months; <i>p</i> = 0.07). Treatment was well tolerated.</p><p><strong>Conclusion: </strong>In this real-world Belgian cohort, TTF with standard therapy yielded survival outcomes consistent with or exceeding pivotal trials. While clinical benefit appears evident, implementation remains challenged by financial costs. Further prospective Belgian studies are needed to assess cost-effectiveness and quality-of-life impact.</p>","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":" ","pages":"394-402"},"PeriodicalIF":1.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148473725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global burden of cardiovascular diseases attributable to environmental and occupational risk factors, 1990-2021: an analysis for the global burden of disease study 2021.","authors":"Shiwen Wang, Xueyao Zhang","doi":"10.1080/17843286.2026.2701970","DOIUrl":"10.1080/17843286.2026.2701970","url":null,"abstract":"<p><strong>Background: </strong>Cardiovascular disease (CVD) remains a leading cause of mortality worldwide. Emerging evidence indicates that environmental and occupational risk factors (EORF) are significantly associated with its onset. However, the current global burden of CVD attributable to these exposures remains unclear.</p><p><strong>Method: </strong>Using data from the Global Burden of Disease (GBD) Study, we estimated the number of deaths, disability-adjusted life years (DALYs), age-standardized death and DALY rates attributable to EORF from 1990 to 2021. Estimates were stratified by sex, region, and year. Additionally, we assessed the association between the EORF-related CVD burden and sociodemographic index (SDI).</p><p><strong>Result: </strong>We found that CVD mortality due to EORF increased from 4.42million in 1990 to 6.44 million in 2021 (95% UI: 4.99-7.77), representing a 45.7% increase, while DALYs rose from 103million in 1990 to 138 million in 2021 (95% UI: 109-165), marking a 34.0% rise. During this period, age-standardized death and DALY rates globally showed a downward trend, decreasing by 38.5% and 38.9% respectively. At the national and regional levels, Western Australia and high SDI regions in Australia demonstrated significant improvements in EORF-related CVD burden. Additionally, men exhibit higher CVD burdens compared to women.</p><p><strong>Conclusion: </strong>Our findings indicate that the overall burden of CVD attributable to EORF has increased substantially in the current population, highlighting significant room for improvement in prevention and control strategies. There is an urgent need to implement effective interventions targeting major EORF to mitigate the global CVD burden associated with these modifiable risks.</p>","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":" ","pages":"413-426"},"PeriodicalIF":1.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148438650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}